Lead Sponsor

Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•1. Patients diagnosed with Multiple Sclerosis (Poser and McDonald criteria).
•2. Secondary progressive MS patients with EDSS ≥ 5.5 and ≤ 9.
•3. Patients with treatment failure defined by: no response to immunomodulators / immunosuppressants, and showing activity in the form of 1 relapse in the last year or 0.5 points in EDSS progression.
•4. Patients with no MS relapse and no steroid treatment within the month prior to inclusion.
•5. Patients who give written consent to participate in the study. -

•1. History of current pathology or current laboratory results indicative of any severe disease.
•2. Pacemaker or metallic implants that prevent MR imaging.
•3. Inability to complete questionnaires.
•4. Refusal to give informed consent.
•5. Predicted impossibility for a biopsy of at least 30 grams of fat tissue.
•6. Positive screening test for HIV, Hepatitis B or Hepatitis C.
•7. History of malignancy.
•8. Having been in treatment with any investigational drug or have undergone any experimental procedure in the 3 months prior to baseline.
•9. Body mass index\> 40 kg/m2.
•10. Patients who have been treated with prohibited concomitant medication during the month prior to inclusion in the study.
•11. Pregnancy or lactation
•\-

Related studies

NCT03922724 · Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, and more

NCT07362654 · Celiac Disease, Gluten Sensitivity, and more

NCT02579967 · Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency, and more

NCT06948110 · Autoimmune Diseases

NCT06342713 · Healthy Participants, Healthy Subjects, and more

Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis